title: Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study.
abstract: BACKGROUND
  Venous thromboembolism is a common complication of cancer and its treatments. Treatment of cancer-associated thrombosis (CAT) differs from treatment of thrombosis in noncancer patients, requiring a daily injection of low-molecular-weight heparin (LMWH) for 6 months instead of an oral anticoagulant. Previous research suggested LMWH is an acceptable intervention in the treatment of CAT, yet clinical practice and therapeutic opportunities have changed in the decade since the study was conducted. Furthermore, in the previous study there was acknowledged selection bias in participant recruitment. There is increasing clinical use of the novel oral anticoagulants, although their efficacy and safety is yet to be demonstrated within the cancer population. The experience of patients receiving anticoagulation for CAT will inform future practice with respect to quality of life and adherence to anticoagulation therapy.
  
  
  OBJECTIVE
  To explore the acceptability of long-term LMWH for the treatment of CAT in the contexts of living with cancer and quality of life.
  
  
  METHODS
  Qualitative study of cancer patients who had been receiving LMWH for at least 3 months for CAT was undertaken. Audiotaped semistructured interviews were conducted and transcribed. Thematic analysis was undertaken until theoretical saturation.
  
  
  METHODS
  Fourteen patients attending a palliative care or CAT clinic were interviewed. Participants had been receiving LMWH for a median 6 months.
  
  
  RESULTS
  Participants reported distressing symptoms associated with symptomatic CAT, which they rated as worse than their cancer experiences. LMWH was considered an acceptable intervention despite challenges of long-term injections. Several adaptive techniques were reported to optimize ongoing injections. Participants would only favor a novel oral anticoagulant if it was equivalent to LMWH in efficacy and safety.
  
  
  CONCLUSIONS
  Although LMWH remains an acceptable intervention for the treatment of CAT, its long-term use is associated with bruising and deterioration of injection sites. These are considered an acceptable trade-off against their strongly negative experiences of symptomatic venous thromboembolism.
authors.affiliation: Department of Palliative Medicine, Royal Gwent Hospital, Newport, Wales, UK.
authors.forename: Siwan
authors.initials: S
authors.lastname: Seaman
authors.affiliation: Marie Curie Palliative Care Research Unit, Cardiff University, Cardiff, Wales, UK.
authors.forename: Annmarie
authors.initials: A
authors.lastname: Nelson
authors.affiliation: Marie Curie Palliative Care Research Unit, Cardiff University, Cardiff, Wales, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Noble
keywords: NOAC; acceptability; cancer; experience; qualitative; quality of life; venous thromboembolism
references.citation: N Engl J Med. 2009 Dec 10;361(24):2342-52
references.pmid: 19966341
references.citation: Eur J Cancer. 2002 Feb;38(3):349-58
references.pmid: 11818199
references.citation: Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8
references.pmid: 12814979
references.citation: Chest. 2012 Feb;141(2 Suppl):e1S-e23S
references.pmid: 22315262
references.citation: N Engl J Med. 2010 Dec 23;363(26):2499-510
references.pmid: 21128814
references.citation: Palliat Med. 2008 Dec;22(8):965-8
references.pmid: 18952751
references.citation: J Thromb Haemost. 2007 Mar;5(3):632-4
references.pmid: 17319909
references.citation: N Engl J Med. 2013 Feb 21;368(8):699-708
references.pmid: 23216615
references.citation: J Clin Oncol. 1997 Jan;15(1):110-5
references.pmid: 8996131
references.citation: J Clin Oncol. 2000 Sep;18(17):3078-83
references.pmid: 10963635
references.citation: Lancet Oncol. 2008 Jun;9(6):577-84
references.pmid: 18510989
references.citation: Chest. 2008 Jun;133(6 Suppl):454S-545S
references.pmid: 18574272
references.citation: JAMA. 2005 Feb 9;293(6):715-22
references.pmid: 15701913
references.citation: Chest. 2012 Feb;141(2 Suppl):e419S-e496S
references.pmid: 22315268
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2189-204
references.pmid: 23669224
references.citation: Blood. 2002 Nov 15;100(10):3484-8
references.pmid: 12393647
references.citation: N Engl J Med. 2012 Apr 5;366(14):1287-97
references.pmid: 22449293
references.citation: Ann Oncol. 2006 Feb;17(2):205-10
references.pmid: 16239231
references.citation: Thromb Haemost. 1995 Oct;74(4):1055-8
references.pmid: 8560413
references.citation: Postgrad Med J. 2007 Nov;83(985):671-4
references.pmid: 17989265
references.citation: J Thromb Haemost. 2013 Jan;11(1):56-70
references.pmid: 23217107
references.citation: Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96
references.pmid: 17000884
references.citation: Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9
references.pmid: 20386546
references.citation: Arch Intern Med. 2002 Aug 12-26;162(15):1729-35
references.pmid: 12153376
references.citation: Am J Med. 2006 Dec;119(12):1062-72
references.pmid: 17145251
references.citation: N Engl J Med. 2003 Jul 10;349(2):146-53
references.pmid: 12853587
references.citation: Palliat Med. 2005 Apr;19(3):197-201
references.pmid: 15920933
references.citation: J Exp Clin Cancer Res. 2008 Jul 18;27:21
references.pmid: 18634550
references.citation: Palliat Med. 2007 Sep;21(6):473-6
references.pmid: 17846086